CDK4/6 inhibitors are a class of medicines used to treat certain types of metastatic breast cancer, which is cancer that has spread to other parts of the body.

Apr 14, 2023 · CDK4/6 inhibitors are a class of drugs that target particular enzymes, called CDK4 and CDK6. CDK stands for cyclin-dependent kinase, and it is an enzyme that is important for cell division. CDK4/6 inhibitors interrupt signals that stimulate the proliferation of malignant (cancerous) cells.

Mar 18, 2022 · Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular transition into S phase and are important for the initiation, growth and survival of many cancer types....

The current FDA approved drugs are all CDK4/6 inhibitors targeting CDK4 and CDK6, two enzymes that control the cell cycle checkpoint transition checkpoint from the G1 to the S phase of the cell cycle.

Feb 27, 2025 · CDK4/6 inhibitors are drugs designed to interrupt the growth of cancer cells. CDK4/6 inhibitors are pills that are used in combination with hormone therapy (also called endocrine therapy) to treat some hormone receptor-positive breast cancers.

In this article, we explore the biological importance of CDK4/6 in cancer therapy, the development of resistance to monotherapy, and a short overview of PROTAC (Proteolysis Targeting Chimera), a unique and pioneering technique for degrading CDK4/6 enzymes.

Feb 26, 2024 · Aberrant activation of the cyclin-dependent kinase 4 and 6 (CDK4/6) pathway, independent of mitogenic signaling, engenders uncontrolled breast cancer cell proliferation. Consequently, the...

In this Review, Fassl et al. discuss basic biology of CDK4 and CDK6 kinases, studies that led to identification of CDK4/6 as excellent anti-cancer targets, the growing application of CDK4/6 inhibitors in cancer treatment and the promise these compounds hold for future therapies.

Jan 14, 2022 · Cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) and their activating partners, D-type cyclins, link the extracellular environment with the core cell cycle machinery. Constitutive activation of cyclin D–CDK4/6 represents the driving force of tumorigenesis in …

Breast cancer is the second largest cancer in the world, and it has highest mortality rate in women worldwide. The aberrant activation of the cyclin-dependent kinase 4 and 6 (CDK4/6) pathway plays an important role in uncontrolled breast cancer cell proliferation. Therefore, targeting CDK4/6 to impr …